News | August 22, 2023
LEO Pharma to acquire Timber Pharmaceuticals
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
An accomplished R&D leader and champion of the application of AI to drug discovery
Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Subscribe To Our Newsletter & Stay Updated
